| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | FIBROGEN INC COM | 1,230,391 | 26,970,000 | 12.28% | ||
| 2 | Atara Biotherapeutics Inc | 803,458 | 25,261,000 | 11.50% | ||
| 3 | ARRAY BIOPHARMA INC 3 06/01/2020 | 22,534,000 | 22,210,000 | 10.11% | PRN | |
| 4 | RETROPHIN INC COM | 1,007,660 | 20,415,000 | 9.29% | ||
| 5 | EPIZYME INC COM | 1,492,700 | 19,196,000 | 8.74% | ||
| 6 | ASSEMBLY BIOSCIENCES INC | 1,887,069 | 18,040,000 | 8.21% | ||
| 7 | KITE PHARMA INCORPORATED | 281,400 | 15,668,000 | 7.13% | ||
| 8 | FLEX PHARMA INC COM | 933,691 | 11,214,000 | 5.10% | ||
| 9 | COLLEGIUM PHARMACEUTICAL INC COM | 465,118 | 10,284,000 | 4.68% | ||
| 10 | Life Technologies Corp | 840,462 | 8,623,000 | 3.92% | ||
| 11 | Nabriva Therapeutics AG | 835,530 | 7,938,000 | 3.61% | ||
| 12 | KINDRED BIOSCIENCES INC | 1,323,431 | 6,882,000 | 3.13% | ||
| 13 | GENVEC INC | 1,986,413 | 4,589,000 | 2.09% | ||
| 14 | CELLADON CORP | 2,843,170 | 2,985,000 | 1.36% | ||
| 15 | ONCOTHYREON INC COM N/C EFF 6/ | 943,500 | 2,585,000 | 1.18% | ||
| 16 | AKARI THERAPEUTICS PLC | 100,709 | 2,417,000 | 1.10% | ||
| 17 | FORWARD PHARMA A/S | 101,995 | 2,403,000 | 1.09% | ||
| 18 | FIVE PRIME THERAPEUTICS INC | 149,000 | 2,293,000 | 1.04% | ||
| 19 | CALITHERA BIOSCIENCES INC | 415,480 | 2,256,000 | 1.03% | ||
| 20 | GILEAD SCIENCES INC | 3,255 | 2,148,000 | 0.98% | Call | |
| 21 | Orexigen Therapeutics, Inc. | 937,958 | 1,979,000 | 0.90% | ||
| 22 | QLT INC | 638,900 | 1,699,000 | 0.77% | ||
| 23 | VALEANT PHARMACEUTICALS INTL | 1,265 | 1,347,000 | 0.61% | Call | |
| 24 | Catalyst Biosciences | 56,000 | 261,000 | 0.12% | ||
| 25 | REGULUS THERAPEUTICS INC | 1,280 | 35,000 | 0.02% | Call |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-15-041435, filed 2015.11.16).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
